11,900 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, HoldingsChannel reports. The fund purchased 11,900 shares of the biopharmaceutical company’s stock, valued at approximately $9,194,000.

Other large investors have also recently bought and sold shares of the company. Fairvoy Private Wealth LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $844,000. Ritholtz Wealth Management increased its position in shares of Regeneron Pharmaceuticals by 13.9% during the 1st quarter. Ritholtz Wealth Management now owns 1,408 shares of the biopharmaceutical company’s stock worth $1,088,000 after purchasing an additional 172 shares in the last quarter. Blue Trust Inc. lifted its holdings in Regeneron Pharmaceuticals by 223.0% during the 1st quarter. Blue Trust Inc. now owns 772 shares of the biopharmaceutical company’s stock valued at $596,000 after purchasing an additional 533 shares during the last quarter. RFG Advisory LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $1,063,000. Finally, Fifth Third Wealth Advisors LLC boosted its position in Regeneron Pharmaceuticals by 49.7% in the first quarter. Fifth Third Wealth Advisors LLC now owns 2,470 shares of the biopharmaceutical company’s stock valued at $1,908,000 after buying an additional 820 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.5%

NASDAQ REGN opened at $620.14 on Friday. The stock has a fifty day moving average of $665.93 and a 200-day moving average of $729.12. The stock has a market capitalization of $65.56 billion, a P/E ratio of 15.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 52 week low of $514.79 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the previous year, the company posted $8.22 earnings per share. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on REGN. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Leerink Partners reiterated a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research report on Monday, May 18th. Finally, Guggenheim raised their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $792.65.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.